Prostate Cancer - Results from #1700

68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. March 8, 2024

What can patient-reported experience measures tell us about the variation in patients' experience of prostate cancer care? A cross-sectional study using survey data from the National Prostate Cancer Audit in England. March 8, 2024

MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial. March 7, 2024

Lower baseline testosterone level is related to earlier development of castration resistance in metastatic prostate cancer: a multi-center cohort study. March 7, 2024

Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer. March 7, 2024

Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort. March 7, 2024

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients. March 7, 2024

Gender disparity trends in genitourinary oncology academic publishing over the past 3 decades: A bibliometric analysis. March 7, 2024

Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range March 6, 2024

Critical evaluation of artificial intelligence as a digital twin of pathologists for prostate cancer pathology. March 6, 2024

MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study. March 6, 2024

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). March 6, 2024

Complications of immuno-oncology care: what urologist should know. March 6, 2024

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer. March 6, 2024

ArteraAI Announced as the First-and-Only Predictive Test for Therapy Personalization in the 2024 NCCN Guidelines® for Prostate Cancer March 5, 2024

Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK. March 5, 2024

The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy. March 5, 2024

A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. March 5, 2024

Urologists' and general practitioners' knowledge, beliefs and practice relevant for opportunistic prostate cancer screening: a PRISMA-compliant systematic review. March 5, 2024

Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer. March 5, 2024

Page 86 of 1458